Indo Global Exchange (IGEX) fair value: what the stock is really worth
As of Nov 10, 2026: fair value (intrinsic value) of Indo Global Exchange stock $0.00, price $0.00, that is 0.3% below the price, quality 40 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
Indo Global Exchange(s) PTE, Ltd., a development stage company, focuses on providing financial market access to customers worldwide. Its platform provides financial market access to approximately 30 equity exchanges for trading in securities and contract for differences.
Show moreShow less
The company is based in Jakarta, Indonesia.
Stock analysis
Indo Global Exchange (IGEX) currently trades at $0.0004, while our estimate is $0.0004, so the stock looks roughly fairly valued today (gap 0.3%).
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $0.0004 (bear) to $0.0004 (bull), the price of $0.0004 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Indo Global Exchange reported revenue of $3.5K in FY2022 versus $10.7K in FY2015, a compound −14.8%/yr. Reported net income was −$193K in FY2025.
Key figures
Market cap $2.8M Micro · P/E ratio 0.0 · EPS (TTM) $0.0200 · Return on assets (EBIT) −65.8% (4-year average) · Operating margin −532% · Revenue (TTM) $3.5K · Free cash flow $973K · Net debt $1.0M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).
What moves the price
The share trades about 50% below its 52-week high and 100% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 0%, IGEX screens cheaper than that median.
Fair Value
Bear$0.0004Fair Value $0.0004Bull$0.0004
Price $0.0004 · Downside -0.3%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Quality Score breakdown
Overall quality40/100
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Profitability3
How much profit the company makes from its sales and capital
Quality Growth80
Are margins and returns getting better?
Cashflow100
Do the profits arrive as real cash?
Financial strength50
Debt, balance sheet and risk of trouble
Investment33
Does it invest with discipline instead of growing at any price?
Low Volatility36
How calm the share price moves, does not count
Price momentum7
Price momentum of the last 3 to 12 months, does not count
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.53/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.2%
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−13.0%
’14
’15
’16
’18
’19
’22
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−6,263.9% (2016) → −61,707.5% (2022)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−25.9%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −27.6% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 606 stocks
Beats the industry median on 4/6 measures
Overall it ranks above its industry peers.
Valuation
Quality Score40 · Bottom 25%
Fair Value upside−0.3% · Above median
Profitability
Return on assets−3.0% · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Indo Global Exchange Fair Value". https://www.fairvalue-calculator.com/stock/IGEX
Frequently asked questions
Is Indo Global Exchange (IGEX) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $0.0004 versus a price of $0.0004, about 0% lower (fairly valued).
What is the fair value of IGEX?
Our estimate for Indo Global Exchange is $0.0004 (as of Nov 10, 2026), built from audited fundamentals. The current price: $0.0004.
What is the quality score of IGEX?
Indo Global Exchange has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Indo Global Exchange (IGEX)?
Our calculated price target is the estimate of $0.0004 (as of Nov 10, 2026). Cautious scenario $0.0004, optimistic scenario $0.0004. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Indo Global Exchange stock forecast for 2026?
Our estimate puts fair value at $0.0004, about 0% lower versus a price of $0.0004 (fairly valued). Cautious scenario $0.0004, optimistic scenario $0.0004. The calculation is refreshed regularly with new filings.
What is the revenue of Indo Global Exchange (IGEX)?
Indo Global Exchange reported trailing-twelve-month revenue of about $3.5K (latest available figure, as of Nov 10, 2026).
What growth is priced into Indo Global Exchange (IGEX)?
For today's price to be fair in a discounted-cash-flow model, Indo Global Exchange would have to grow free cash flow by -25.9 % per year for five years (discount rate 9.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 6 years revenue grew -24.9 % per year. As of Nov 10, 2026.
What discount rate (WACC) does the fair value of IGEX use?
Our models discount Indo Global Exchange at 9.4 %: a base by market capitalisation (nano), damped by beta 0.87, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Indo Global Exchange that is -25.9 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.4 %) and the same formula as our fair value.
How much growth has Indo Global Exchange (IGEX) delivered so far?
Over the past 6 years revenue at Indo Global Exchange grew -24.9 % a year. The price currently implies free-cash-flow growth of -25.9 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Indo Global Exchange (IGEX) growing?
The median revenue growth in the sector is +5.9 % a year. That is the yardstick for the growth priced into Indo Global Exchange (-25.9 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Indo Global Exchange (IGEX)?
The free-cash-flow yield on the price is 34.17 %: that much free cash flow Indo Global Exchange produces per unit of market value. When it exceeds the discount rate of our models (9.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Indo Global Exchange (IGEX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Indo Global Exchange it is $0.0004 per share (as of Nov 10, 2026), against a price of $0.0004.
Is Indo Global Exchange stock overvalued or undervalued in 2026?
As of Nov 10, 2026, IGEX trades above its calculated fair value: price $0.0004, fair value $0.0004, a gap of about −0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IGEX?
No. The price is what the market pays today ($0.0004); the fair value is what the company's own numbers justify ($0.0004). For Indo Global Exchange the two are $0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Indo Global Exchange worth?
The market values Indo Global Exchange at about $2.8M (market capitalisation, as of Nov 10, 2026). Per share that is $0.0004; our models calculate a fair value of $0.0004 per share.
What do the bullish and bearish scenarios say about IGEX?
Our models span a range for Indo Global Exchange: cautious scenario $0.0004, base $0.0004, optimistic $0.0004 per share (as of Nov 10, 2026, price $0.0004). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of IGEX?
Indo Global Exchange trades at a price-to-earnings ratio of 0.0 (as of Nov 10, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.0004 is built from several models across several years. Other multiples: P/B 0.6.
How far is IGEX from its 52-week high?
Indo Global Exchange trades at $0.0004, about 50% below its 52-week high of $0.0008 and 100% above the low of $0.0002 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0004 is for.
Which stocks are comparable to Indo Global Exchange?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Indo Global Exchange stock attractive at the current price?
The data as of Nov 10, 2026: price $0.0004, calculated fair value $0.0004 (−0%), Quality Score 40/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Indo Global Exchange itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Indo Global Exchange (IGEX)?
The closing price on Nov 10, 2026 was $0.0004. Our estimate is $0.0004, about 0% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Indo Global Exchange right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band ($0.0004 to $0.0004), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Indo Global Exchange
How large is the market capitalisation of Indo Global Exchange (IGEX)?
The market capitalisation of Indo Global Exchange is $2.8M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Indo Global Exchange (IGEX)?
Earnings per share at Indo Global Exchange are $0.0200 (price ÷ EPS = P/E 0.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the EBIT return on assets of Indo Global Exchange (IGEX)?
On an EBIT basis the return on assets of Indo Global Exchange is −65.8% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Indo Global Exchange (IGEX)?
The operating margin of Indo Global Exchange is −532% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much net debt does Indo Global Exchange (IGEX) carry?
The net debt of Indo Global Exchange is $1.0M (fiscal year 2025, ≈ 1.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Indo Global Exchange in the live analysis
One click puts Indo Global Exchange on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 10, 2026